Etoposide, cisplatin, epirubicin chemotherapy in the treatment of pediatric liver tumors

Michela Casanova; Maura Massimino; Andrea Ferrari; Filippo Spreafico; Luigi Piva; Jorgelina Coppa; Roberto Luksch; Graziella Cefalo; Monica Terenziani; Daniela Polastri; Franca Fossati Bellani; Vincenzo Mazzaferro

doi:10.1080/08880010590921441

Etoposide, cisplatin, epirubicin chemotherapy in the treatment of pediatric liver tumors

Michela Casanova, Maura Massimino, Andrea Ferrari, Filippo Spreafico, Luigi Piva, Jorgelina Coppa, Roberto Luksch, Graziella Cefalo, Monica Terenziani, Daniela Polastri, Franca Fossati Bellani, Vincenzo Mazzaferro

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journal › Article

Abstract

To discuss the potential benefit of a chemotherapy regimen including etoposide (etoposide, cisplatin, epirubicin [EPE]), the authors report a single-institutional experience regarding 13 children with hepatoblastoma (HB) and 7 with hepatocellular carcinoma (HCC). Chemotherapy achieved partial response in 8/9 HB and in 4/5 HCC. Eight initially unresectable HB subsequently had liver resection. Event-free survival and overall survival at 5 years were 84 and 88% for HB (non-metastatic cases: 91 and 100%), 29% for HCC. EPE chemotherapy seems to be effective in the treatment of childhood malignant liver tumors. Etoposide could be suggested as part of intensive multidrug regimens for HCC and high-risk HB.

Original language	English
Pages (from-to)	189-198
Number of pages	10
Journal	Pediatric Hematology and Oncology
Volume	22
Issue number	3
DOIs	https://doi.org/10.1080/08880010590921441
Publication status	Published - Apr 2005

Keywords

Chemotherapy
Cis platin
Epirubicin
Etoposide
Hepatoblastoma
Hepatocellular carcinoma

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology
Cancer Research

Access to Document

10.1080/08880010590921441

Fingerprint Dive into the research topics of 'Etoposide, cisplatin, epirubicin chemotherapy in the treatment of pediatric liver tumors'. Together they form a unique fingerprint.

Cite this

Casanova, M., Massimino, M., Ferrari, A., Spreafico, F., Piva, L., Coppa, J., Luksch, R., Cefalo, G., Terenziani, M., Polastri, D., Bellani, F. F., & Mazzaferro, V. (2005). Etoposide, cisplatin, epirubicin chemotherapy in the treatment of pediatric liver tumors. Pediatric Hematology and Oncology, 22(3), 189-198. https://doi.org/10.1080/08880010590921441

Etoposide, cisplatin, epirubicin chemotherapy in the treatment of pediatric liver tumors. / Casanova, Michela ; Massimino, Maura ; Ferrari, Andrea ; Spreafico, Filippo ; Piva, Luigi ; Coppa, Jorgelina ; Luksch, Roberto; Cefalo, Graziella; Terenziani, Monica; Polastri, Daniela; Bellani, Franca Fossati; Mazzaferro, Vincenzo.

In: Pediatric Hematology and Oncology, Vol. 22, No. 3, 04.2005, p. 189-198.

Research output: Contribution to journal › Article

Casanova, Michela ; Massimino, Maura ; Ferrari, Andrea ; Spreafico, Filippo ; Piva, Luigi ; Coppa, Jorgelina ; Luksch, Roberto ; Cefalo, Graziella ; Terenziani, Monica ; Polastri, Daniela ; Bellani, Franca Fossati ; Mazzaferro, Vincenzo. / Etoposide, cisplatin, epirubicin chemotherapy in the treatment of pediatric liver tumors. In: Pediatric Hematology and Oncology. 2005 ; Vol. 22, No. 3. pp. 189-198.

@article{729cb6fd0da7454b9ece85acbd3fd780,

title = "Etoposide, cisplatin, epirubicin chemotherapy in the treatment of pediatric liver tumors",

abstract = "To discuss the potential benefit of a chemotherapy regimen including etoposide (etoposide, cisplatin, epirubicin [EPE]), the authors report a single-institutional experience regarding 13 children with hepatoblastoma (HB) and 7 with hepatocellular carcinoma (HCC). Chemotherapy achieved partial response in 8/9 HB and in 4/5 HCC. Eight initially unresectable HB subsequently had liver resection. Event-free survival and overall survival at 5 years were 84 and 88% for HB (non-metastatic cases: 91 and 100%), 29% for HCC. EPE chemotherapy seems to be effective in the treatment of childhood malignant liver tumors. Etoposide could be suggested as part of intensive multidrug regimens for HCC and high-risk HB.",

keywords = "Chemotherapy, Cis platin, Epirubicin, Etoposide, Hepatoblastoma, Hepatocellular carcinoma",

author = "Michela Casanova and Maura Massimino and Andrea Ferrari and Filippo Spreafico and Luigi Piva and Jorgelina Coppa and Roberto Luksch and Graziella Cefalo and Monica Terenziani and Daniela Polastri and Bellani, {Franca Fossati} and Vincenzo Mazzaferro",

year = "2005",

month = apr,

doi = "10.1080/08880010590921441",

language = "English",

volume = "22",

pages = "189--198",

journal = "Pediatric Hematology and Oncology",

issn = "0888-0018",

publisher = "Informa Healthcare",

number = "3",

}

TY - JOUR

T1 - Etoposide, cisplatin, epirubicin chemotherapy in the treatment of pediatric liver tumors

AU - Casanova, Michela

AU - Massimino, Maura

AU - Ferrari, Andrea

AU - Spreafico, Filippo

AU - Piva, Luigi

AU - Coppa, Jorgelina

AU - Luksch, Roberto

AU - Cefalo, Graziella

AU - Terenziani, Monica

AU - Polastri, Daniela

AU - Bellani, Franca Fossati

AU - Mazzaferro, Vincenzo

PY - 2005/4

Y1 - 2005/4

N2 - To discuss the potential benefit of a chemotherapy regimen including etoposide (etoposide, cisplatin, epirubicin [EPE]), the authors report a single-institutional experience regarding 13 children with hepatoblastoma (HB) and 7 with hepatocellular carcinoma (HCC). Chemotherapy achieved partial response in 8/9 HB and in 4/5 HCC. Eight initially unresectable HB subsequently had liver resection. Event-free survival and overall survival at 5 years were 84 and 88% for HB (non-metastatic cases: 91 and 100%), 29% for HCC. EPE chemotherapy seems to be effective in the treatment of childhood malignant liver tumors. Etoposide could be suggested as part of intensive multidrug regimens for HCC and high-risk HB.

AB - To discuss the potential benefit of a chemotherapy regimen including etoposide (etoposide, cisplatin, epirubicin [EPE]), the authors report a single-institutional experience regarding 13 children with hepatoblastoma (HB) and 7 with hepatocellular carcinoma (HCC). Chemotherapy achieved partial response in 8/9 HB and in 4/5 HCC. Eight initially unresectable HB subsequently had liver resection. Event-free survival and overall survival at 5 years were 84 and 88% for HB (non-metastatic cases: 91 and 100%), 29% for HCC. EPE chemotherapy seems to be effective in the treatment of childhood malignant liver tumors. Etoposide could be suggested as part of intensive multidrug regimens for HCC and high-risk HB.

KW - Chemotherapy

KW - Cis platin

KW - Epirubicin

KW - Etoposide

KW - Hepatoblastoma

KW - Hepatocellular carcinoma

UR - http://www.scopus.com/inward/record.url?scp=20944448885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20944448885&partnerID=8YFLogxK

U2 - 10.1080/08880010590921441

DO - 10.1080/08880010590921441

M3 - Article

C2 - 16020101

AN - SCOPUS:20944448885

VL - 22

SP - 189

EP - 198

JO - Pediatric Hematology and Oncology

JF - Pediatric Hematology and Oncology

SN - 0888-0018

IS - 3

ER -